chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a physician concerning a female patient who on 10/22/01 was vaccinated with a dose of pneumococcal vaccine 23 polyvalent. Subsequently, the patient developed hives below the injection site. It was reported that the site was red and indurated. Unspecified medical attention was sought. The patient's husband also experienced an injection site reaction (WAES01104370) after vaccination the same week with pneumococcal vaccine 23 polyvalent. Additional information has been requested.
Moderna COVID-19 Vaccine EUA Three days following the injection I had most of the symptoms. The injection site was hot, hard and quite painful (I couldn't sleep on that side of my body for three nights). I felt generally unwell and achy. After about three days all of my symptoms went down and most of them were gone except for I could still feel a small amount of swelling under the skin that continued to go down. On Tuesday Feb 10, almost a week out I started to experience an itching feeling that increased throughout the day to a deep itch that feels like it goes down to my bone. The injection site has become red, hot and hard again and the lymph node in my left armpit is extremely painful and swollen. I feel dizzy and nauseous.
Patient received her second dose of the Moderna Covid-19 vaccine as an expired vaccine.; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received her second dose of the Moderna Covid-19 vaccine as an expired vaccine.) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 24-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received her second dose of the Moderna Covid-19 vaccine as an expired vaccine.). On 21-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Patient received her second dose of the Moderna Covid-19 vaccine as an expired vaccine.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications was reported. No treatment drug details was reported.   Reporter did not allow further contact
Patient has been vomiting all night and today. She has a headache, chills, tired, pain, arm pain, no appetite. Her whole body hurts and has been shaking.
No additional AE information provided; VARIVAX was administered to a patient on 12/20/2022 after a supported temperature excursion that took place on 12/1/202; This spontaneous report was received from the Medical assistant, and refers to a 12-month-old male patient.  The patient's medical history, concurrent conditions, and concomitant therapies were not provided.  On 20-DEC-2022, the patient was vaccinated with first dose of varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, 0.5 milliliter, lot # W021741 and expiration date: 10-JUL-2024 or lot# W018825 and expiry date: 14-JUN-2024 (two possible lot numbers provided), administered subcutaneously for prophylaxis at right thigh (strength was not provided), after temperature excursion, which took place on 01-DEC-2022. Event occurred due freezer probe was switched out, and it took longer for probe to start working (19.47 F for 30-40 minutes or 50 minutes, discrepancy information). The vaccine was purchased with public funds, and the patient was vaccinated at Private Doctor's Office/ Hospital. No additional adverse event information was provided.   This in one of the several reports from the same reporter.; Sender's Comments:  US-009507513-2301USA001100: US-009507513-2301USA000947: US-009507513-2301USA000926: US-009507513-2301USA001204: US-009507513-2301USA001215: US-009507513-2301USA001055: US-009507513-2301USA000912:
My throat was scratchy, and my nose felt raw. The next day my nose started to run, and I had sneezing and coughing. The 3rd day my nose really started to run a lot. I tested negative on Tuesday and positive on Wednesday December 21, 2022, for COVID-19. I called my doctor and had a virtual appointment and he prescribed PAXLOVID which I started to take later on the December 22, 2022. By this time, I had a slight fever of 99.7 and a mild headache had developed. My teeth hurt really bad for some reason. I started to feel better after 2 doses of the PAXLOVID. I still have slight sniffles, cough and some brain fog but I feel I have completely recovered.
After about 15 minutes, patient start feeling dizzy and had headache, In addition, she was unable to stay focused.
pt has devel acute autoimmune demyelinating polyneuropathy (GBS) 1wk p/vax;pt also had viral synd 3wk prior to disease onset;
Swelling of breast tissue under left arm; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021 at 13:00 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes mellitus, blood pressure high, anxiety and depression. The patient did not have a history of allergies to medications, food, or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 12Mar2021 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Concomitant medications included metformin (MANUFACTURER UNKNOWN), ergocalciferol (VITAMIN D2), rosuvastatin calcium (CRESTOR) and lisinopril (MANUFACTURER UNKNOWN), all for unknown indication. The patient did not receive any other vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021 at 13:00, the patient experienced swelling of breast tissue under left arm. The patient did not receive any treatment for the reported event. Adverse event did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the event swelling of breast tissue under left arm was not resolved at the time of report.   No follow-up attempts are needed. No further information is expected.
Redness at injection site to back side of left arm approximately 2in long and 1.5 in wide.  Injection site warm to touch.  Left upper arm swollen. Client states arm hurts and burns.  Clients also states that she applied ice to site for a few minutes while at work.
Small bruise at injection site. Entire upper arm very sore. Soreness began evening of 13th and got progressively worse on 11-15. Movement of arm is painful. Patient reports that her mother is a nurse and that her mother said injection given approximately 3 inches too high. Patient has had multiple influenza vaccinations in past without pain (but with occasional bruising).
1 - pain in injection site 2 - swollen, painful nipples 2 days after the shot (just the nipples, not my entire breasts)  3 - dizziness & fatigue 4 - ringing in the ears and Blacked Out the next morning after the shot 5 - been going through menopause and have not had a period in several months, within 4 days after the shot, my menstrual cycle started 6 - lower back pain, not sure if it is from menstrual cycle or kidneys - will be seeking medical advice from Kaiser 7 - itchiness and tingling sensations in different parts of my body started 1/10 (10 days after the shot)
Continued Shortness of Breath, low Oxygenation levels of 90-93
Red, tender, swollen (L) lateral buttocks after receiving PNEUMOVAX vaccine on 5/5/11. (+) fever 101.3.
malaise; fatigue; body aches; chills; fever; cough; This is a spontaneous from a contactable consumer (patient). A female patient of an unspecified age received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, lot number: unknown) via unspecified route of administration on an unspecified date as DOSE 2, SINGLE for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. Historical vaccine included the patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, lot number: unknown) via unspecified route of administration on an unspecified date as DOSE 1, SINGLE for COVID-19 immunisation. It was reported that about 8 hours after 2nd vaccine, the patient started experiencing malaise and fatigue which as time wore on she developed body aches, chills, fever and cough. The outcome of the events was unknown.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
Major symptoms, roughly 20 hours after vaccination, 10-15 minutes after waking, while walking and standing: - Extreme pain in right hip joint. Pain is sharp, stabbing, burning. Pain radiates down leg, and right foot numb and tingly - Overheating - Lightheadedness, blurred vision, confusion - Fainting or loss of consciousness, falling to ground  Timeline of events:  2021-04-08 13:00 Injected with Johnson & Johnson 13:00 - 13:15 Very slight nausea 13:15 - 22:00 Very slight nausea and fatigue 22:30 Lymph nodes in neck feel swollen, ears feel slightly clogged (typical early cold symptoms) 23:30 Insomnia and chills  2021-04-09 00:00 - 07:30 Insomnia, poor sleep, and cycles of chills and overheating while trying to sleep or sleeping. Stronger nausea than before 07:30 Wake up, knees feel slightly weak when walking 07:35 - 07:40 While walking inside a market. Right hip joint begins to hurt with sharp, stabbing, hot pain. The pain radiates down right thigh. Right foot begins to feel numb and tingle. This pain increased over 5 minutes, to excruciating levels, with right leg feeling numb, and sharp stabbing tingles in right foot. Difficult to walk normally 07:40 - 07:45 Pain becomes overbearing, and market counter used for support. Begin to feel light headed. Begin to feel hot, and begin to overheat within ~2 minutes. Walk outside market (outside temperature 32 - 40F) to cool down. Lean on car hood for support, and become increasingly lightheaded. Vision becomes blurry. Stumble and fall onto face. Regain consciousness after unknown time, groggy and with blurred vision, lightheaded feeling. Attempt to stand and fall again onto face. Regain consciousness after unknown time. No longer feeling extremely hot. After roughly 1 minute, regain clear vision and lucidity. Pain in hip and leg completely subsided 07:45 - 09:00 Driven to hospital. Treated by hospital staff for laceration in forehead requiring 7 sutures. EKG reports normal. Concussion check negative. 09:00 - 00:00 Occasional nausea, fatigue, weakness (same as weak cold)  2021-04-10  11:00 While walking and standing in line. Right hip joint begins to hurt, with pain radiating down right thigh. Right foot begins to feel numb and tingle. Begin to feel warm. Hip Pain remains at manageable level, and walking normally is easy. Hip pain is roughly 1/3 of pain of 2021-04-09.  2021-04-11 07:30 - 11:00 Occasional slight pain in right hip and left hip joints. Hip pain is sharp and burning, and roughly 1/10 of pain from 2021-04-09.
Rash all over body. On head, elbows and hands raised rash and blisters. Taking Benadryl every four hours and hydrocortisone cream.
Patient developed a fever of 102 F, mother discovered this around 10:00 PM and gave him ibuprofen granuoles she had purchased abroad previous to July of 2013.
ACUTE DVT OF BILAT LEGS, UNSPECIFIED VEINS 11/3/2022 ABNL LIVER FUNCTION STUDY ACUTE DVT OF BILAT LEGS, UNSPECIFIED VEINS 11/3/2022 JAUNDICE ACUTE DVT OF BILAT LEGS, UNSPECIFIED VEINS 11/3/2022 ACUTE DVT OF INFERIOR VENA CAVA
1st dose 12 months ago, failed to receive the 2nd; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose 12 months ago on an unknown date, via unknown route in unknown injection site).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, the patient failed to return within the recommended time frame to receive the second dose, which led to incomplete course of vaccination. This case was linked with case US2021239191, reported by same reporter for different patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021239191:Same reporter.
Due to patient age she should have received Pfizer rather than Moderna. No reactions noted during the wait time after receiving the dose.
14cm x 11cm erythematous area with slight elevation warm to touch at site of R arm.
inadvertently administered with 1.0 ml of the vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of ACCIDENTAL OVERDOSE (inadvertently administered with 1.0 ml of the vaccine) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040A21A and 016B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Apr-2021, the patient experienced ACCIDENTAL OVERDOSE (inadvertently administered with 1.0 ml of the vaccine). On 10-Apr-2021, ACCIDENTAL OVERDOSE (inadvertently administered with 1.0 ml of the vaccine) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.   This case was linked to MOD-2021-073944, MOD-2021-073978, MOD-2021-073920 (E2B Linked Report).; Sender's Comments:  MOD-2021-073944:Cross linked case MOD-2021-073978:Cross linked case MOD-2021-073920:Cross linked case
Vaccine date 3-26-04 (Friday) Mother noticed on Sunday pain fine raised red rash from diaper up to chest area. No itching. No temp. Was treated per Dr for ear infection 3-10-04 with Septra 0.75 tsp twice daily for 10 days prior to event.
This spontaneous report as received from a nurse refers to a unspecified number of patients of unknown age and gender. On an unknown date the patients received improperly stored doses of M-M-R II (dosage, route of administration and indication were not provided)   which were exposed 8.5C for 15 minutes. No adverse effect were reported. This is one of several reports received from the same reporter. Additional information has been requested.
PATIENT REPORTED FEELING LIGHT HEADED. HE HAD SYNCOPAL EPISODE WITH OBSERVER PRESENT FOR  2-3 SECONDS. HE ALSO REPORT FEELING NAUSEA WITH SWEAT. HE HAD A  HEART RATE 63 WITH OK  PULSE . HE HAS NOT TAKEN ANY MEDICATION  , NO ALLERGIES.  PATIENT  WAS ADVICED TO LIE FLAT WITH FEET ELEVAT AND STAY HYDRATED.  PATIENT ADVICED TO NOTIFY  IF NO IMPROVENT IN SYMPTOMS.  WHEN SYMPTOM  NOT  IMPROVING,  HE WAS BROUGHT  TO THE TENT. BP:127/87  HR :55  . PATIENT REPORTED IMPROVEMENT IN NAUSEA, DIZZINESS AND BY 13:20PM . AT 13:27 , PATIENT LEFT WITH WIFE AFTER SYMPTOM WAS RESOLVED
Patient returned to pharmacy about 30 minutes after vaccination with complaint of minor pain in left forearm and being able to feel a mass in forearm.
healthy 37 M was given a first dose of .25/booster dose administered instead of full dose; This spontaneous case was reported by an other health care professional and describes the occurrence of ACCIDENTAL UNDERDOSE (healthy 37 M was given a first dose of .25/booster dose administered instead of full dose) in a 36-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 ml. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (healthy 37 M was given a first dose of .25/booster dose administered instead of full dose). At the time of the report, ACCIDENTAL UNDERDOSE (healthy 37 M was given a first dose of .25/booster dose administered instead of full dose) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.  Patient received the second dose of 0.5 ml on 28 Dec 2021. Patient was not experiencing any symptoms.   Most recent FOLLOW-UP information incorporated above includes: On 28-Dec-2021: Follow up received included reporter information, patient demographics and second dose details added in inarrative.
Itching; Exhausted; headache; back pain; This is a spontaneous report received from a contactable consumer (patient). A 42-years-old female non-pregnant patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number: En6208, Expiration date was not reported), via an unspecified route of administration in arm left on 12Mar2021 at 11:45 AM (at the age of 42-year-old) as a dose 1, single for COVID-19 immunization. The patient's medical history included lupus, hashimoto. The patient had known allergies to intravenous iodine. The patient's concomitant medications in two weeks included hydroxychloroquine sulfate (PLAQUENIL [HYDROXYCHLOROQUINE SULFATE]), escitalopram oxalate (LEXAPRO), vit d [vitamin d nos], all were taken for an unspecified indication. It was reported that, the patient was not pregnant at time of vaccination. No other vaccine in four weeks was reported. No covid prior vaccination and no covid tested post vaccination. On 12Mar2021 at 13:45, 2 hours after vaccination, the patient experienced back pain. On 13Mar2021 at 11:45, next day after vaccination, the patient experienced exhausted and headache with still pain. On 15Mar2021 at 11:45, the patient experienced itching (on 3rd day). Treatment was not received for the events. The outcome of the events was not recovered.  Follow-up attempts are completed. No further information is expected.
Information has been received from a health professional concerning a 19 year old female with seasonal allergy to dust pollen and a history of asthma who on an unknown date complained mild feeling of achiness and flu symptoms after the second dose of GARDASIL (route and site not reported). The third dose of GARDASIL (route and site not reported) was given at 3:00 PM (date not reported). The patient woke up the next morning with severe symptom of flu, vertigo and nausea. The patient "felt like she had influenza without the respiratory symptom". The patient was bedridden for 36 hours. The patient was treated with montelukast sodium (MSD), CLARITIN, COMBIVENT and PATADAY, QHS. Follow up information was received from a Certified Nurse Practitioner concerning the 19 year old female student who on 29-JUN-2007 was vaccinated intramuscularly in the left arm with her first dose of GARDASIL. On 24-SEP-2007 was vaccinated IM with the second dose in the left deltoid and on 18-JAN-2008 was vaccinated IM in the right deltoid with the third dose. Suspect vaccine therapy included the third IM dose of hepatitis B virus vaccine rHBsAg (manufacturer unknown), on 31-AUG-2007 the second IM dose in the left arm of hepatitis B virus vaccine rHBsAg (manufacture unknown) an an IM dose in the right deltoid of MENACTRA and on 18-JAN-2008 a IM 0.5 ml dose of tetanus toxoid booster in the left deltoid. There was no illness reported at the time of vaccination. The patient did OK after the first dose of GARDASIL. On 29-SEP-2007, the patient felt slightly ill after the second dose of GARDASIL which resolved spontaneously. On 29-SEP-2007, the patient felt slightly ill after the second dose of GARDASIL which resolved spontaneously. On 19-JAN-2008, the next morning after the third vaccine dose, the patient experienced vertigo, nausea, felt like influenza without upper respiratory infection. At the time of report the patient had recovered. No further information is available.
Clammy with no temperature; No appetite; Hot & Cold; Nausea; Very Tired; This spontaneous case was reported by a consumer and describes the occurrence of COLD SWEAT (Clammy with no temperature), DECREASED APPETITE (No appetite), FEELING OF BODY TEMPERATURE CHANGE (Hot & Cold), NAUSEA (Nausea) and FATIGUE (Very Tired) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, the patient experienced COLD SWEAT (Clammy with no temperature), DECREASED APPETITE (No appetite), FEELING OF BODY TEMPERATURE CHANGE (Hot & Cold), NAUSEA (Nausea) and FATIGUE (Very Tired). At the time of the report, COLD SWEAT (Clammy with no temperature), DECREASED APPETITE (No appetite), FEELING OF BODY TEMPERATURE CHANGE (Hot & Cold), NAUSEA (Nausea) and FATIGUE (Very Tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment medications were reported.
This case was reported by a pharmacist and described the occurrence of allergic reaction in a subject of unspecified age and gender who was vaccinated with Fluarix for prophylaxis. The subject's medical history included allergy to antibiotic and allergy to penicillin. The subject had received influenza virus vaccine in previous years with no subsequent adverse events. On an unspecified date in 2006, on or before 14 November 2006, the subject received unspecified dose of Fluarix. On an unspecified date in 2006, on or before 14 November 2006, less than one year after the vaccination with Fluarix, the subject experienced allergic reaction and hive. The subject was seen in an emergency room. The outcome of the events was not reported.
Patient said the lymph node under her left armpit was swollen and tender and she experienced extreme myalgia and malaise after her shingrix vaccination on 1/8/20 at 4:40pm
Difficulty breathing due to largely occluded larynx on day following flu vaccine injection. Went to clinic for treatment.